These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Thrombotic thrombocytopenic purpura associated with rapidly progressive lupus nephritis: report of two cases. Kapoulas S; Liakos S; Karkavelas G; Ageloudi M; Grekas D; Giannoulis E Clin Nephrol; 2005 Apr; 63(4):297-301. PubMed ID: 15847257 [TBL] [Abstract][Full Text] [Related]
25. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Kanda H; Kubo K; Tateishi S; Sato K; Yonezumi A; Yamamoto K; Mimura T Lupus; 2005; 14(4):288-92. PubMed ID: 15864915 [TBL] [Abstract][Full Text] [Related]
26. Single-dose rituximab in refractory lupus nephritis. Kotagiri P; Martin A; Hughes P; Becker G; Nicholls K Intern Med J; 2016 Aug; 46(8):899-901. PubMed ID: 27242250 [TBL] [Abstract][Full Text] [Related]
27. Diffuse proliferative crescentic lupus nephritis with normal renal function. Gupta V; Sachdeva S; Khan AS; Haque SF Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):343-5. PubMed ID: 22382232 [TBL] [Abstract][Full Text] [Related]
28. Non-albumin proteinuria as a parameter of tubulointerstitial inflammation in lupus nephritis. Kwon OC; Park Y; Lee JS; Oh JS; Kim YG; Lee CK; Yoo B; Hong S Clin Rheumatol; 2019 Jan; 38(1):235-241. PubMed ID: 30094751 [TBL] [Abstract][Full Text] [Related]
29. The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus. Bojic M; Kozakowski N; Bécède M; Kerschbaumer A; Bobacz K Kidney Int; 2017 Jul; 92(1):271-272. PubMed ID: 28647000 [No Abstract] [Full Text] [Related]
30. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Sazliyana S; Mohd Shahrir MS; Kong CT; Tan HJ; Hamidon BB; Azmi MT Lupus; 2011 Oct; 20(12):1260-6. PubMed ID: 21844115 [TBL] [Abstract][Full Text] [Related]
31. [Lupus nephritis in Senegal: study of 42 cases]. Dia D; Ka EF; Cissé M; Pouye A; Niang NM; Kane A; Dieng MT; Niang A; Ka MM; Diouf B; Ndiaye B; Moreira-Diop T Dakar Med; 2007; 52(1):23-6. PubMed ID: 19102087 [TBL] [Abstract][Full Text] [Related]
32. Diagnosis and treatment of lupus nephritis. Oyama JH Med Clin North Am; 1971 Jan; 55(1):71-87. PubMed ID: 4923437 [No Abstract] [Full Text] [Related]
33. The value of early renal biopsy in systemic lupus erythematosus patients presenting with renal involvement. Hsieh YP; Wen YK; Chen ML Clin Nephrol; 2012 Jan; 77(1):18-24. PubMed ID: 22185964 [TBL] [Abstract][Full Text] [Related]
34. Glomerular disease: perspectives on maintenance therapy in lupus nephritis. Balow JE Nat Rev Nephrol; 2012 Feb; 8(3):136-8. PubMed ID: 22310950 [TBL] [Abstract][Full Text] [Related]
35. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Yap DY; Ma MK; Tang CS; Chan TM Nephrology (Carlton); 2012 Nov; 17(8):676-80. PubMed ID: 22817609 [TBL] [Abstract][Full Text] [Related]
36. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil]. Sixdorf U; Bauer H; Märker-Hermann E Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267 [TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus preventive strategies in lupus nephritis and renal vasculitis treated with immunosuppressants. Tan HZ; Choo JCJ; Tan BH; Mok IYJ; Lim CC Lupus; 2020 Mar; 29(3):351-352. PubMed ID: 31986963 [No Abstract] [Full Text] [Related]
38. Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes. Hanaoka H; Kuwana M; Takeuchi T Int J Rheum Dis; 2015 Sep; 18(7):768-75. PubMed ID: 26179413 [TBL] [Abstract][Full Text] [Related]
39. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Brugos B; Sebestyen L; Tarr T; Vincze Z Pharmazie; 2014 Jun; 69(6):442-4. PubMed ID: 24974578 [TBL] [Abstract][Full Text] [Related]